{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:03:53Z","timestamp":1794647033816,"version":"4.9.1"},"reference-count":50,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The 48\u2010week, phase 2 SLEek study (NCT03978520) evaluated the efficacy and safety of upadacitinib (JAK inhibitor) and elsubrutinib (BTK inhibitor) alone or in combination (ABBV\u2010599) in adults with moderately to severely active systemic lupus erythematosus (SLE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients were randomized 1:1:1:1:1 to elsubrutinib 60 mg and upadacitinib 30 mg once daily (ABBV\u2010599 high dose), elsubrutinib 60 mg and upadacitinib 15 mg once daily (ABBV\u2010599 low dose), elsubrutinib 60 mg once daily (QD), upadacitinib 30 mg QD, or placebo QD. The primary endpoint was the proportion of patients achieving both Systemic Lupus Erythematosus Responder Index 4 (SRI\u20104) and glucocorticoid dose \u226410 mg QD at week 24. Additional assessments through week 48 included British Isles Lupus Assessment Group\u2010Based Composite Lupus Assessment (BICLA) and Lupus Low Disease Activity State (LLDAS) responses, number of flares, time to first flare, and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study enrolled 341 patients. The ABBV\u2010599 low dose and elsubrutinib arms were discontinued after a planned interim analysis showed lack of efficacy (no safety concerns). More patients achieved the primary endpoint with upadacitinib (54.8%;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.028) and ABBV\u2010599 high dose (48.5%;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.081) versus placebo (37.3%). SRI\u20104, BICLA, and LLDAS response rates were higher for both upadacitinib and ABBV\u2010599 high dose versus placebo at weeks 24 and 48. Flares were reduced, and time to first flare through week 48 was substantially delayed with both upadacitinib and ABBV\u2010599 high dose versus placebo. No new safety signals were observed beyond those previously reported for upadacitinib or elsubrutinib.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Upadacitinib 30 mg alone or in combination with elsubrutinib (ABBV\u2010599 high dose) demonstrated significant improvements in SLE disease activity and reduced flares and were well tolerated through 48 weeks.<\/jats:p>\n                    <jats:p>\n                      <jats:boxed-text content-type=\"graphic\" position=\"anchor\">\n                        <jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" mimetype=\"image\/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic\/art42926-toc-0001-m.png\">\n                          <jats:alt-text>image<\/jats:alt-text>\n                        <\/jats:graphic>\n                      <\/jats:boxed-text>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.42926","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T02:05:55Z","timestamp":1719281155000},"page":"1518-1529","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Patients With Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled Trial"],"prefix":"10.1002","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4514-2382","authenticated-orcid":false,"given":"Joan T.","family":"Merrill","sequence":"first","affiliation":[{"name":"Oklahoma Medical Research Foundation  Oklahoma City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"University of Occupational and Environmental Health Japan  Kitakyushu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"D'Cruz","sequence":"additional","affiliation":[{"name":"King's College London and Guy's Hospital  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Vila\u2010Rivera","sequence":"additional","affiliation":[{"name":"GCM Medical Group  San Juan Puerto Rico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Siri","sequence":"additional","affiliation":[{"name":"CAICI Institute  Rosario Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Zeng","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences and Peking Union Medical College  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0098-1083","authenticated-orcid":false,"given":"Amit","family":"Saxena","sequence":"additional","affiliation":[{"name":"New York University Grossman School of Medicine  New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Aringer","sequence":"additional","affiliation":[{"name":"University Medical Center and Faculty of Medicine, Technische Universit\u00e4t Dresden  Dresden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin M.","family":"D'Silva","sequence":"additional","affiliation":[{"name":"AbbVie  North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Cheng","sequence":"additional","affiliation":[{"name":"AbbVie  North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0959-2025","authenticated-orcid":false,"given":"Mohamed\u2010Eslam F.","family":"Mohamed","sequence":"additional","affiliation":[{"name":"AbbVie  North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Siovitz","sequence":"additional","affiliation":[{"name":"AbbVie Deutschland  Ludwigshafen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Bhatnagar","sequence":"additional","affiliation":[{"name":"AbbVie  North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u2010Claude","family":"Gaudreau","sequence":"additional","affiliation":[{"name":"AbbVie  North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thao T.","family":"Doan","sequence":"additional","affiliation":[{"name":"AbbVie  North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Friedman","sequence":"additional","affiliation":[{"name":"AbbVie  North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,8,7]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1100359"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2022.101814"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30546-X"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8142368"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-00948-y"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/09612033221147479"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06500-3"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-021-01626-9"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152103"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076578"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/nolysy"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-018-0031-x"},{"key":"e_1_2_8_16_1","first-page":"S1015","article-title":"Pharmacodynamics of a novel Jak1 selective inhibitor in rat arthritis and anemia models and in healthy human subjects","volume":"65","author":"Voss J","year":"2013","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_8_17_1","article-title":"Prescribing information","author":"RINVOQ\u00ae (upadacitinib)","year":"2023","journal-title":"AbbVie"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2018.1484269"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222335"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400928"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34473"},{"key":"e_1_2_8_22_1","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman DD","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24698"},{"key":"e_1_2_8_24_1","first-page":"S885","article-title":"Evaluation of treatment success in systemic lupus erythematosus clinical trials: development of the British Isles Lupus Assessment Group\u2010Based Composite Lupus Assessment Endpoint. Poster presented at: 2011 American College of Rheumatology\/Association of Rheumatology Health Professionals Annual Meeting; November 4\u20139, 2011; Chicago, IL","volume":"63","author":"Wallace DJ","year":"2011","journal-title":"Arthritis Rheum"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207726"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1191\/096120399680411281"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051135"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2005.23889.x"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(22)00092-3"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.662223"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15261"},{"key":"e_1_2_8_32_1","first-page":"303","article-title":"Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity","volume":"24","author":"Gabay C","year":"1997","journal-title":"J Rheumatol"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00581-5"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212728"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15803"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0605-6"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1550"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00739-3"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27221"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002735"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-015-0043-3"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39962"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912196"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42391"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.635531"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02607-1"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02546-6"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2018-000258"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214530"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10020243"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2016.1112270"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.42926","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T20:20:42Z","timestamp":1759954842000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.42926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1002\/art.42926"],"URL":"https:\/\/doi.org\/10.1002\/art.42926","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,7]]},"assertion":[{"value":"2023-11-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}